Who is sponsoring NCT06612827?

NCT06612827 is sponsored by Centre Francois Baclesse.

What drugs are being tested in NCT06612827?

Interventions in NCT06612827: organoid etablishment.

What condition does NCT06612827 study?

NCT06612827 studies Undifferentiated Carcinoma.

Is NCT06612827 still recruiting?

NCT06612827 is currently recruiting now. Last updated 24 December 2025.

Last reviewed 2025-12-24 · How we verify

NCT06612827: OCAPI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

Recruiting now Last updated 24 December 2025

What this trial tests

trial testing organoid etablishment in Undifferentiated Carcinoma in 20 participants. Currently enrolling.

Timeline

5 March 2025

Primary endpoint
15 December 2028

15 December 2032

Quick facts

Lead sponsor	Centre Francois Baclesse
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	20
Start date	5 March 2025
Primary completion	15 December 2028
Estimated completion	15 December 2032
Sites	1 location across France

Drugs / interventions tested

organoid etablishment

Conditions studied

Undifferentiated Carcinoma — all drugs for Undifferentiated Carcinoma →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

18 and older, any sex, with Undifferentiated Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Undifferentiated Carcinoma

Currently open trials in the same condition.

NCT00565851 — Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients Wit · Phase 3 · active not recruiting

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
NCT06603506 — Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06612827 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 24 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06612827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing